Multiple Myeloma Clinical Trial
— 07-REVOfficial title:
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma
This is a multi-institution, non-randomized, open label, Phase IIa prospective trial to
evaluate the safety and tolerability of maintenance lenalidomide after allogeneic
hematopoietic stem cell transplantation (HCT).
Lenalidomide maintenance therapy will start between day 60 and 90 after allogeneic HCT at a
starting dose of 10mg PO once daily. Dose escalation and de-escalation will be performed
depending on tolerability of lenalidomide. Dose range is 5mg every other day to 5 - 25 mg
given daily on days 1-21 of a 28-day cycle for 12 cycles maximum or maximum of 12 months
from first dose of study drug.
Patients will be followed until 28 days from completing the 12th planned cycle of
lenalidomide maintenance or 12 months from first dose of study drug, which ever comes first,
(14 to 15 months after receiving the allograft) or discontinuation of study drug.
Status | Completed |
Enrollment | 30 |
Est. completion date | March 2014 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - One prior allograft from an 8/8 or 7/8 allele matched related or unrelated donor, received 60 to 90 days prior to initiation of lenalidomide - Meet the diagnostic criteria of symptomatic myeloma at anytime prior to allogeneic HCT - Have high-risk multiple myeloma - Received = three (3) prior lines of therapy. Prior therapies may include: combination chemotherapy, monotherapy, lenalidomide and autologous HCT. Localized radiation therapy does not count as a single line of therapy. Previous progression on lenalidomide does not exclude participation in the study. - Received a reduced intensity conditioning regimen - Received or are receiving a GVHD prophylaxis regimen of a calcineurin inhibitor in combination with either methotrexate, mycophenolate mofetil (MMF) or sirolimus - Karnofsky performance score = 80 or ECOG = 2 - There must be at least 50% donor chimerism and no evidence of falling donor chimerism within 1 month of enrollment - Laboratory test results within range, within 14 days prior to initiation of lenalidomide - All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®. Exclusion Criteria: - Disease progression at time of study entry - Patients with any grade III-IV GVHD at the time of study entry - Patients requiring additional immunosuppressive therapy to control acute GVHD other than corticosteroids and immunosuppressive agents used for prophylaxis. - Concomitant use of other investigational agents - Patients who have received donor lymphocyte infusions - Active CNS malignancy - Uncontrolled bacterial, viral, or fungal infections - Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ < 5 years from study entry. - Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide. - Known positive for HIV or active infectious hepatitis. - Women who are pregnant or breastfeeding. - New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | City of Hope National Medical Center | Duarte | California |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | The University of Texas, M.D. Anderson Cancer Center | Houston | Texas |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | University of Minnesota Medical Center | Minneapolis | Minnesota |
United States | University of Pennsylvania Hospital Center | Philadelphia | Pennsylvania |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
United States | H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Center for International Blood and Marrow Transplant Research | Celgene Corporation, National Marrow Donor Program |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma. | 12 months | Yes | |
Secondary | To estimate the incidences of = grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide. | 13 months | Yes | |
Secondary | To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT. | 13 Months | Yes | |
Secondary | To determine time to disease progression and overall survival after lenalidomide. | 13 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |